Hansa On a High After CHMP Thumbs-Up For Idefirix
Positive Opinion For Kidney Transplant Drug
Sweden's Hansa Biopharma has taken an important step closer to becoming a commercial-stage company with the backing of European regulators for Idefirix, although launch plans have been impacted by the COVID-19 crisis.
You may also be interested in...
EU approval is likely for the eight medicines that got the thumbs up this week from the European Medicines Agency's drug evaluation committee, the CHMP. The panel held fire on one product it had been considering and also issued its first rejection of 2020.
The French major and partner Regeneron expect to file Dupixent for the rare skin disease next year after a Phase III trial of the blockbuster hit its primary and secondary endpoints.
Elacestrant has become the first oral SERD to generate positive topline results in a pivotal study as a monotherapy versus standard of care for ER+/HER2- advanced or metastatic breast cancer.